Dec 05, 2019 09:11 JST

Source: Eisai

Eisai to Present New Research on Eribulin (Halaven) at 42nd Annual San Antonio Breast Cancer Symposium


TOKYO, Dec 05, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest information on its in-house discovered and developed eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: HALAVEN, "eribulin") will be presented during the 42nd San Antonio Breast Cancer Symposium (SABCS2019). The symposium will be held from December 10 through 14, 2019, in San Antonio, Texas in the United States.

A total of five poster presentations will be given at this year's SABCS including the study results evaluating absolute lymphocyte count at the baseline with eribulin as a predictor of overall survival from the post-hoc analysis of two Phase III clinical studies of eribulin in patients with advanced or metastatic breast cancer.

Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

 



About Eisai
Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai: Application for Additional Indication of Anti Cancer Agent Lenvima for Unresectable Thymic Carcinoma Submitted in Japan
July 31 2020 08:31 JST
 
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the Alzheimer's Association International Conference (AAIC) 2020
July 22 2020 16:04 JST
 
Eisai: Smartphone App for Vital Signs Measurement of Patients With the Novel Coronavirus Infection Experimental Study Project Adopted as AMED Project
July 20 2020 11:36 JST
 
Eisai: Initiation of New Phase III Clinical Study (Ahead 3-45) of ban2401 Preclinical (Asymptomatic) Alzheimer's Disease
July 14 2020 08:20 JST
 
Eisai: Industry-Academia-Government Joint Development Agreement Aiming for Drug Discovery for Systemic Lupus Erythematosus by Practical Application of Toll-Like Receptor Research Concluded
July 13 2020 10:47 JST
 
Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer's Disease
July 09 2020 11:20 JST
 
Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma
July 09 2020 11:11 JST
 
Eisai: New Drug Application for In-House Developed New Anti-insomnia Drug Dayvigo Accepted in Hong Kong
July 08 2020 13:33 JST
 
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tazemetostat for EZH2 Gene Mutation-Positive Follicular Lymphoma
July 08 2020 13:16 JST
 
Eisai to Launch In-House Developed New Anti-insomnia Drug Dayvigo (Lemborexant) with Indication for Insomnia in Japan
July 06 2020 08:33 JST
 
More Press release >>

Latest Press Release


More Latest Release >>